文献速递贫血与红细胞疾病造血干细胞移植与细胞治疗

美国复发或难治性重型再生障碍性贫血患者的单倍体骨髓移植(BMT CTN 1502):一项多中心、单臂、2期试验

Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial.
PubMed 文献 · Lancet Haematol · 2022-07-27

BMT CTN 1502是一项在美国14个中心开展的单臂2期试验,纳入32例复发或难治性重型再生障碍性贫血患者(31例接受移植),采用减低强度预处理、相关单倍体供者及移植后环磷酰胺为基础的GVHD预防。1年总生存率为81%(95%CI 62-91),6例(19%)死亡,常见3-5级不良事件包括心血管改变15例(48%)等。

要点

  • 1年总生存率为81%(95%CI 62-91),24例(77%)患者1年时存活且植入成功。
  • 6例(19%)死亡,归因于疾病和骨髓移植失败。
  • 作者认为该方案可获得极佳总生存且GVHD轻微,可扩大移植可及性。

核心结论

  • 采用该方案的单倍体骨髓移植在免疫抑制治疗无效的患者中获得极佳总生存且GVHD轻微,可扩大所有人群的骨髓移植可及性。
  • 作者认为在临床实践中,该方案现在可考虑作为重型再生障碍性贫血挽救治疗的标准方法。
  • 作者强调从骨髓采集物中获得高细胞剂量(>2·5 × 10^8 个有核骨髓细胞/kg受者理想体重)对该方案的成功至关重要。

研究设计与样本

  • BMT CTN 1502是一项在美国学术骨髓移植中心开展的单臂、2期临床试验,注册号NCT02918292。
  • 纳入儿童和成人(≤75岁)复发或难治性重型再生障碍性贫血患者,要求东部肿瘤协作组评分0或1、Karnofsky或Lansky评分≥60%,且存在合格的相关单倍体供者。
  • 2017年5月1日至2020年8月30日从14个中心入组32例患者,31例接受骨髓移植。
  • 预处理为减低强度方案:兔抗胸腺细胞球蛋白总量4·5 mg/kg、环磷酰胺14·5 mg/kg每日×2天、氟达拉滨30 mg/m2每日×5天、全身照射200 cGy单次。
  • GVHD预防:移植后环磷酰胺为基础,联合吗替麦考酚酯口服15 mg/kg每日三次至最大1 g每日三次(最大日剂量3000 mg)从第5天至第35天,他克莫司口服或静脉从第5天至第180天按机构标准维持血清浓度10-15 ng/mL。

主要发现

  • 31例接受移植患者的中位年龄为24·9岁(IQR 10·4-51·3),中位随访24·3个月(IQR 12·1-29·2)。
  • 31例接受移植患者中19例(61%)为男性,12例(39%)为女性;13例(42%)经中心报告为非白人,19例(61%)来自代表性不足的种族和族裔群体。
  • 31例中24例(77%)在1年时存活且植入成功,1例(3%)存活伴自体恢复。
  • 1年总生存率为81%(95%CI 62-91)。
  • 常见3-5级不良事件(7例及以上):肝功能异常7例(23%)、心血管改变15例(48%,包括窦性心动过速、心力衰竭、心包炎)、胃肠道问题10例(32%)、营养障碍7例(23%)、呼吸系统疾病8例(26%)。

临床怎么用

  • 作者认为在临床实践中,该方案现在可考虑作为重型再生障碍性贫血挽救治疗的标准方法。
  • 作者强调从骨髓采集物中获得高细胞剂量(>2·5 × 10^8 个有核骨髓细胞/kg受者理想体重)对该方案的成功至关重要。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Relapsed severe aplastic anaemia is a marrow failure disorder with high morbidity and mortality. It is often treated with bone marrow transplantation at relapse post-immunosuppressive therapy, but under-represented minorities often cannot find a suitably matched donor. This study aimed to understand the 1-year overall survival in patients with relapsed or refractory severe aplastic anaemia after haploidentical bone marrow transplantation. METHODS: We report the outcomes of BMT CTN 1502, a single-arm, phase 2 clinical trial done at academic bone marrow transplantation centres in the USA. Included patients were children and adults (75 years or younger) with severe aplastic anaemia that was refractory (fulfilment of severe aplastic anaemia disease criteria at least 3 months after initial immunosuppressive therapy) or relapsed (initial improvement of cytopenias after first-line immunosuppressive therapy but then a later return to fulfilment of severe aplastic anaemia disease criteria), adequate performance status (Eastern Cooperative Oncology Group score 0 or 1, Karnofsky or Lansky score ≥60%), and the presence of an eligible related haploidentical donor. The regimen used reduced-intensity conditioning (rabbit anti-thymocyte globulin 4·5 mg/kg in total, cyclophosphamide 14·5 mg/kg daily for 2 days, fludarabine 30 mg/m2 daily for 5 days, total body irradiation 200 cGy in a single fraction), related HLA-haploidentical donors, and post-transplantation cyclophosphamide-based graft-versus-host disease (GVHD) prophylaxis. Additionally, for GVHD prophylaxis, mycophenolate mofetil was given orally at a dose of 15 mg/kg three times a day up to 1 g three times a day (maximum dose 3000 mg per day) from day 5 to day 35, and tacrolimus was given orally or intravenously from day 5 to day 180 as per institutional standards to maintain a serum concentration of 10-15 ng/mL. The primary endpoint was overall survival 1 year after bone marrow transplantation. All patients treated per protocol were analysed. This study is complete and is registered with ClinicalTrials.gov, NCT02918292. FINDINGS: Between May 1, 2017, and Aug 30, 2020, 32 patients with relapsed or refractory severe aplastic anaemia were enrolled from 14 centres, and 31 underwent bone marrow transplantation. The median age was 24·9 years (IQR 10·4-51·3), and median follow-up was 24·3 months (IQR 12·1-29·2). Of the 31 patients who received a transplant, 19 (61%) were male and 12 (39%) female. 13 (42%) patients were site-reported as non-White, and 19 (61%) were from under-represented racial and ethnic groups; there were four (13%) patients who were Asian, seven (23%) Black, one (3%) Hawaiian/Pacific Islander, and one (3%) more than one race, with seven (23%) patients reporting Hispanic ethnicity. 24 (77%) of 31 patients were alive with engraftment at 1 year, and one (3%) patient alive with autologous recovery. The 1-year overall survival was 81% (95% CI 62-91). The most common grade 3-5 adverse events (seen in seven or more patients) included seven (23%) patients with abnormal liver tests, 15 (48%) patients with cardiovascular changes (including sinus tachycardia, heart failure, pericarditis), ten (32%) patients with gastrointestinal issues, seven (23%) patients with nutritional disorders, and eight (26%) patients with respiratory disorders. Six (19%) deaths, due to disease and unsuccessful bone marrow transplantation, were reported after transplantation. INTERPRETATION: Haploidentical bone marrow transplantation using this approach results in excellent overall survival with minimal GVHD in patients who have not responded to immunosuppressive therapy, and can expand access to bone marrow transplantation across all populations. In clinical practice, this could now be considered a standard approach for salvage treatment of severe aplastic anaemia. Attention to obtaining high cell doses (>2·5 × 108 nucleated marrow cells per kg of recipient ideal bodyweight) from bone marrow harvests is crucial to the success of this approach. FUNDING: US National Heart, Lung, and Blood Institute and US National Cancer Institute.

来源:Lancet Haematol,查看原文。版权归原作者所有。

引用

  1. DeZern AE, Eapen M, Wu J, et al. Haploidentical bone marrow transplantation in patients with relapsed or refractory severe aplastic anaemia in the USA (BMT CTN 1502): a multicentre, single-arm, phase 2 trial. Lancet Haematol. 2022. PMID: 35907408. doi:10.1016/S2352-3026(22)00206-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。